Literature DB >> 27216487

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

Anna Rickli1, Olivier D Moning1, Marius C Hoener2, Matthias E Liechti3.   

Abstract

The present study investigated interactions between the novel psychoactive tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at monoamine receptors and transporters compared with the classic hallucinogens lysergic acid diethylamide (LSD), psilocin, N,N-dimethyltryptamine (DMT), and mescaline. We investigated binding affinities at human monoamine receptors and determined functional serotonin (5-hydroxytryptamine [5-HT]) 5-HT2A and 5-HT2B receptor activation. Binding at and the inhibition of human monoamine uptake transporters and transporter-mediated monoamine release were also determined. All of the novel tryptamines interacted with 5-HT2A receptors and were partial or full 5-HT2A agonists. Binding affinity to the 5-HT2A receptor was lower for all of the tryptamines, including psilocin and DMT, compared with LSD and correlated with the reported psychoactive doses in humans. Several tryptamines, including psilocin, DMT, DiPT, 4-OH-DiPT, and 4-OH-MET, interacted with the serotonin transporter and partially the norepinephrine transporter, similar to 3,4-methylenedioxymethamphetamine but in contrast to LSD and mescaline. LSD but not the tryptamines interacted with adrenergic and dopaminergic receptors. In conclusion, the receptor interaction profiles of the tryptamines predict hallucinogenic effects that are similar to classic serotonergic hallucinogens but also MDMA-like psychoactive properties.
Copyright © 2016 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  DMT; Hallucinogens; LSD; Mescaline; Psilocybin; Tryptamines

Mesh:

Substances:

Year:  2016        PMID: 27216487     DOI: 10.1016/j.euroneuro.2016.05.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  63 in total

Review 1.  Neurotoxicology Syndromes Associated with Drugs of Abuse.

Authors:  Rachel A Caplan; Jonah P Zuflacht; Jed A Barash; Corey R Fehnel
Journal:  Neurol Clin       Date:  2020-11       Impact factor: 3.806

Review 2.  Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.

Authors:  Ricardo Jorge Dinis-Oliveira; Carolina Lança Pereira; Diana Dias da Silva
Journal:  Curr Mol Pharmacol       Date:  2019       Impact factor: 3.339

Review 3.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

4.  Alcohol acutely enhances decoding of positive emotions and emotional concern for positive stimuli and facilitates the viewing of sexual images.

Authors:  Patrick C Dolder; Friederike Holze; Evangelia Liakoni; Samuel Harder; Yasmin Schmid; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2016-09-19       Impact factor: 4.530

5.  Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.

Authors:  Landon M Klein; Nicholas V Cozzi; Paul F Daley; Simon D Brandt; Adam L Halberstadt
Journal:  Neuropharmacology       Date:  2018-02-27       Impact factor: 5.250

6.  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Authors:  Clinton E Canal
Journal:  Handb Exp Pharmacol       Date:  2018

7.  Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

Authors:  Danilo De Gregorio; Argel Aguilar-Valles; Katrin H Preller; Boris Dov Heifets; Meghan Hibicke; Jennifer Mitchell; Gabriella Gobbi
Journal:  J Neurosci       Date:  2020-11-30       Impact factor: 6.167

8.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Authors:  Theresa M Carbonaro; Matthew W Johnson; Ethan Hurwitz; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2017-11-07       Impact factor: 4.530

9.  Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.

Authors:  Randall T Brown; Christopher R Nicholas; Nicholas V Cozzi; Michele C Gassman; Karen M Cooper; Daniel Muller; Chantelle D Thomas; Scott J Hetzel; Kelsey M Henriquez; Alexandra S Ribaudo; Paul R Hutson
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

10.  New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study.

Authors:  Yusuf Ali Altuncı; Melike Aydoğdu; Eda Açıkgöz; Ümmü Güven; Fahriye Düzağaç; Aslı Atasoy; Nebile Dağlıoğlu; Serap Annette Akgür
Journal:  Balkan Med J       Date:  2021-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.